Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
Rhea-AI Summary
Cytokinetics (Nasdaq: CYTK) closed an underwritten public offering on May 8, 2026, selling 11,338,028 common shares (including full exercise of a 1,478,873-share option) at $71.00 per share for gross proceeds of approximately $805 million.
All shares were sold by Cytokinetics; gross proceeds are before underwriting discounts, commissions and offering expenses.
Positive
- Gross proceeds of approximately $805 million
- Full exercise of underwriters’ option for 1,478,873 additional shares
- Sale of 11,338,028 common shares completed
Negative
- Proceeds reported are before underwriting discounts, commissions and offering expenses
- Issuance of 11,338,028 shares increases outstanding share count and shareholder dilution
News Market Reaction – CYTK
In the May 8 session, CYTK gained 3.53%, reflecting a moderate positive market reaction. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Equity offering pricing | Negative | -0.7% | Priced upsized common stock offering at $71 with ~$700M gross proceeds. |
| May 05 | Equity offering proposal | Negative | -2.9% | Proposed ~$650M common stock offering with 30-day underwriter option. |
| Sep 16 | Convertible notes offering | Negative | -4.4% | Priced $650M 1.75% convertible notes due 2031 and refinancing 2027 notes. |
| May 28 | Equity offering closing | Negative | -0.7% | Closed $500M common stock offering at $51 per share under shelf. |
| May 22 | Equity offering pricing | Negative | -17.3% | Priced 9.8M-share offering at $51 per share with 30-day option. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-related announcements for CYTK have consistently been followed by negative single-day price reactions, with all recent equity and convertible offerings showing declines.
Over the past two years, Cytokinetics has repeatedly tapped capital markets via common stock and convertible note offerings. Events on May 5–6, 2026 detailed a proposed and then priced equity raise, while prior offerings in 2024 and a convertible notes deal in September 2025 also led to share price declines. Today’s closing announcement reflects completion of the most recent common stock raise under this pattern of financing to support commercialization and pipeline work.
Key Terms
underwritten public offering financial
prospectus supplement regulatory
prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 1,478,873 additional shares, at a price to the public of
Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies acted as joint book-running managers for the offering. Mizuho acted as lead co-manager for the offering and Citizens Capital Markets, Needham & Company, B. Riley Securities and H.C. Wainwright & Co. acted as co-managers for the offering.
The securities described above were offered by Cytokinetics pursuant to a shelf registration statement (including a base prospectus) filed on February 27, 2025 with the Securities and Exchange Commission (SEC), which has become automatically effective. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and can be accessed for free on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at 866-718-1649 or by email at prospectus@morganstanley.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526 or by email at Prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
